If you are in crisis or thinking about harming yourself, call or text 988 right now. You deserve help today.
Depression Help STL

ServingSt. Louis & St. Charles County

From our survey

Myths St. Louis clinicians still hear about esketamine

Ask a Midwest waiting room about Spravato and most people will shrug. In our survey, 73 percent had never met the word, 21 percent had met it and could not place it, and just 6 percent could explain it.

Those figures come from 443 people across ten states, a general population read rather than a patient registry or a physician sample. That is what makes it useful to a referring clinician. It describes the person in your waiting room, not the literature you already read.

Five hallway assumptions about that person fail against the numbers. Final validation nudged a few figures by a point; gaps this size survived it.

Myth one: my patients have already seen the ads

They have not, and if they had, it would matter little. Beyond the 73 percent who had never heard the name, we asked whose recommendation would get someone to try ketamine or esketamine care. The patient's own doctor won with 74 percent; a close friend or relative drew 18, and ads scraped 2 percent, podcasters 1.

What it changes in clinic: assume no prior exposure and no meaning attached to the word. Treat the term as new every time, and spend your first sentence making unfamiliarity normal rather than correcting a TV impression.

Myth two: the patients who want it will find it online

When we asked where they would begin, 56 percent of respondents named the family doctor, while a psychiatrist or therapist drew 23 percent. Searching online alone drew only 12 percent; 5 percent had no starting point, and asking a friend drew 1.

The open-text item sharpens the point. Of the 443, 319 typed what they would search to find help, and it read like this: "therapist near me," "depressed," "ptsd treatments," "how to overcome depression." One person wrote "someone please help me." Almost nobody typed a drug name, because you cannot search for a word no one has given you.

What it changes in clinic: self-referral is not a real channel. The few who go looking use symptom language and land wherever it leads.

Myth three: it is a cash-pay boutique service

The payer mix our respondents reported does not look boutique. Commercial plans came first at 39 percent and Medicaid nearly level at 37, while TRICARE (5), the uninsured (9), and Medicare (23) filled out a multi-select list.

Stated preference points the same way. Offered insured care with paperwork or quicker care on their own dime, 51 percent took the paperwork, 23 percent would self-fund, and 26 percent were unsure. In ranking provider traits, 85 percent put coverage first or second, and 65 percent said it would decide or weigh heavily on pursuing treatment at all.

What it changes in clinic: raise coverage yourself, early, before the patient decides this is not for people like them. On the Missouri side, whether a site works with MO HealthNet matters for more than a third of this sample.

Myth four: patients are hostile to ketamine

Our first-reaction question about ketamine for depression or PTSD produced this order: cautious but open 34 percent, skeptical 21, then a tie at 18 between the hopeful or curious and those who had never heard of it, with negative last at 9. Open-leaning respondents total 51 percent; the firmly opposed, 9.

What moves the cautious majority looks like credentials, not persuasion: for 59 percent, FDA approval would decide the matter or be a big part of it.

What it changes in clinic: you are not walking into an argument, so do not argue. Make the regulatory and procedural distinctions instead. Esketamine is approved for depression that has resisted treatment, is taken under observation at a certified site with monitoring afterward, never goes home with the patient, and is paired with an oral antidepressant. Clinic IV ketamine for depression is a generic drug used off label. At-home ketamine from an online service is a third thing again. Patients who hear this from you are far less likely to blur it later on their phone, and a plain handout such as Brain Recovery Centers' page on Spravato treatment can carry the same distinctions home.

Myth five: treatment-resistant depression is rare on my panel

Asked about hard-to-treat depression, anxiety, or PTSD, 72 percent of respondents said it had reached them or someone in their life. That 72 splits into 37 percent personally, 22 percent through someone else, and 13 percent both ways; 28 percent had not been touched by it. This is self-report, not a prevalence estimate, but it shows how many people in an ordinary waiting room believe standard treatment has already failed someone they know.

What it changes in clinic: "treatment-resistant" sounds like a specialty label, which is how a patient on a third or fourth trial ends up charted as stable. When you refill a third or fourth agent, rebuild the medication history on paper rather than from memory.

What a practice can do this month

  • Pull patients on a third or later antidepressant trial and check whether the history was ever recorded as failed trials rather than a string of refills.
  • Write one plain page: what esketamine is, what a visit involves, how it differs from IV and at-home ketamine, and who to call about coverage.
  • Settle referrals before you need them. Know which metro sites are certified, which side of the river and which stretch of I-64 or I-70 your patients can realistically reach, and how each handles Medicaid.
  • Let your front desk start the coverage question.

Nothing above is a treatment recommendation or clinical guidance. Whether esketamine or anything else fits a given person is for the clinician who knows their diagnosis, history, and risks. This survey measures public awareness and decision making, nothing more.

Say it plainly: 988 reaches the Suicide and Crisis Lifeline from any phone in the country, by call or by text, free, at any hour. Patients deep in a run of failed trials often stop believing anyone answers a line like that. Telling them costs you ten seconds.

Methodology

We commissioned the survey as this site's publisher and paid its costs. Fielded by Pollfish among its consumer panel members, it had drawn 443 completions by the June 23, 2026 close, from people aged 18 to 64 in Missouri, Illinois, and eight neighboring states. Respondents were general consumers, not clinicians and not screened patients, so the awareness findings describe the public rather than the profession. When a question accepted several answers, the percentages run above 100 in total. The numbers come after the panel was fully validated.